Enrolling By Invitation OBSERVATIONAL NCT05479708

ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma

Postoperative ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma: A Prospective Observational Cohort Study

Sponsor: BAIYONG SHEN

Conditions Pancreatic Cancer Resectable

Interventions ctDNA-based MRD detection

Updated 4 times since 2022 Last updated: Apr 21, 2025 Started: Aug 9, 2023 Primary completion: Nov 30, 2025 Completion: Nov 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Pancreatic Cancer Resectable, this trial is ongoing. The trial is conducted by BAIYONG SHEN and has accumulated 4 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

May 2025 — Present [monthly]

Enrolling By Invitation

Status: Not Yet Recruiting → Enrolling By Invitation
Sep 2024 — May 2025 [monthly]

Not Yet Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting
Sep 2022 — Jul 2024 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BAIYONG SHEN
GeneCast Biotechnology Co., Ltd.

Data source: Ruijin Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China